Cost-effectiveness of statins in the primary prevention of cardiovascular disease: A systematic review and economic analysis for Belgium

Acta Cardiologica

Volumn 64, Issue 1, 2009, Pages 1-10

  Neyt, Mattias ^a   De Laet, Chris ^a   Van Brabandt, Hans ^a   Franco, Oscar ^b,c   Ramaekers, Dirk ^a  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^b UNILEVER RESEARCH   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cardiovascular diseases; Cost benefit analysis; Primary prevention; Review; Statin

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

BELGIUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDICAL FEE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; NICOTINE REPLACEMENT THERAPY; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SMOKING CESSATION PROGRAM; SYSTEMATIC REVIEW;

ASPIRIN; BELGIUM; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK ASSESSMENT; SMOKING CESSATION;

EID: 61849138267     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.64.1.2034354     Document Type: Review

References (27)

1. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160(7): 939-44.
2. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6: 300.
3. Van den Bruel A, Cleemput I, Van Linden A, Schoefs D, Ramaekers D, Bonneux L. Effectivity and cost-effectiveness of treatment for smoking cessation [in Dutch]. Belgian Health Care Knowledge Centre (KCE), Brussels, KCE reports 1A; 2004, 113 pages.
4. Paffenbarger RS, Jr., Blair SN, Lee IM. A history of physical activity, cardiovascular health and longevity: the scientific contributions of Jeremy N Morris, DSc, DPH, FRCP. Int J Epidemiol 2001; 30(5): 1184-92.
5. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Clements G, Capps N, Davey Smith G, Riemersma RA, Ebrahim S. Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev 2007; 1: 1.
6. European Society of Hypertension-European Society of Cardiology Guidelines C. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011-53.
7. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
8. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295(3): 306-13.
9. Ward S, Lloyd J, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. Statins for the Prevention of Coronary Events. Technology assessment report commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence. Sheffield: ScHARR The University of Sheffield; 2005, 385 pages.
10. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala. K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, Third Joint Task Force of E, Other Societies on Cardiovascular Disease Prevention in Clinical P. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601-10.
11. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11(14): 1-160, iii-iv.
12. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, Mustard CA. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006; 332(7542): 659-62.
13. De Backer G. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atheroscler Suppl 2002; 2(4): 13-6.
14. De Laet C, Neyt M, Van Brabandt H, Ramaekers D. Rapid Assessment: Cardiovascular primary prevention in the Belgian GP practice [summary in Dutch and French]. Belgian Health Care Knowledge Centre (KCE), Brussels, KCE reports 52 A (D/2007/10 273/03) 2007, 80 pages.
15. Franco OH, Peeters A, Looman CWN, Bonneux L. Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health 2005; 59(11): 927-33.
16. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 2001; 22(11): 919-25.
17. Spaans JN, Coyle D, Fodor G, Nair R, Vaillancourt R, Grover SA, Coupal L. Application of the 1998 Canadian cholesterol guidelines to a military population: health benefits and cost effectiveness of improved cholesterol management. Can J Cardiol 2003; 19(7): 790-6.
18. Lim SS, Vos T, Peeters A, Liew D, McNeil JJ. Cost-effectiveness of prescribing statins according to Pharmaceutical Benefits Scheme criteria. Med J Aust 2001; 175(9): 459-64.
19. Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med 2003; 163(3): 333-9.
20. Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. Int J Cardiol 2005; 104(2): 213-23.
21. National Institute for Health and Clinical Excellence (NICE). Statins for the prevention of cardiovascular events. London (UK): National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance, no. 94; 2006, 45 pages.
22. Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Ir Med J 2006; 100(1): 144-5.
23. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006; 144(5): 326-36.
24. Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. Primary prevention of cardiovascular disease: Cost-effectiveness comparison. Int J Techn Assessment in Health Care 2007; 23(1): 71-9.
25. Cleemput I, Van Wilder P, Vrijens F, Huybrechts M, Ramaekers D. Guidelines for pharmaco-economic evaluations in Belgium. Belgian Health Care Knowledge Centre (KCE), Brussels, 2008. Report No.: KCE Reports 78A.
26. Simons LA, Simons J, McManus P, Dudley J. Discontinuation rates for use of statins are high. BMJ 2000; 321(7268): 1083-4.
27. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164(4): 208-11.